Quantitation of neurofilament light chain protein in serum and cerebrospinal fluid from patients with multiple sclerosis using the MSD R-PLEX NfL assay
| Autor: | Antigona Ulndreaj, Dorsa Sohaei, Simon Thebault, Oscar D. Pons-Belda, Amaia Fernandez-Uriarte, Christopher Campbell, David Cheo, Martin Stengelin, George Sigal, Mark S. Freedman, Isobel A. Scarisbrick, Ioannis Prassas, Eleftherios P. Diamandis |
|---|---|
| Rok vydání: | 2023 |
| Předmět: | |
| Zdroj: | Diagnosis. |
| ISSN: | 2194-802X 2194-8011 |
| DOI: | 10.1515/dx-2022-0125 |
| Popis: | Objectives Neurofilament light (NfL) chain is a marker of neuroaxonal damage in various neurological diseases. Here we quantitated NfL levels in the cerebrospinal fluid (CSF) and serum from patients with multiple sclerosis (MS) and controls, using the R-PLEX NfL assay, which employs advanced Meso Scale Discovery® (MSD) electrochemiluminescence (ECL)-based detection technology. Methods NfL was quantitated in samples from 116 individuals from two sites (Ottawa Hospital Research Institute and Mayo Clinic), consisting of patients with MS (n=71) and age- and sex-matched inflammatory neurological controls (n=13) and non-inflammatory controls (n=32). Correlation of NfL levels between CSF and serum was assessed in paired samples in a subset of MS patients and controls (n=61). Additionally, we assessed the correlation between NfL levels obtained with MSD’s R-PLEX® and Quanterix’s single molecule array (Simoa®) assays in CSF and serum (n=32). Results Using the R-PLEX, NfL was quantitated in 99% of the samples tested, and showed a broad range in the CSF (82–500,000 ng/L) and serum (8.84–2,014 ng/L). Nf-L levels in both biofluids correlated strongly (r=0.81, p Conclusions We show that MSD’s R-PLEX NfL assay can reliably quantitate levels of NfL in the CSF and serum from patients with MS and controls, where levels correlate strongly with Simoa. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|